Abstract:e13690 Background: Safety net hospitals provide care to a large number of vulnerable patients (pts) regardless of their ability to pay (1). These pts often have barriers to acceptance at many hospitals, including lack of or poor insurance, social and economic challenges. Additionally, pts frequently present with more advanced disease (2). Systemic treatment is preferentially administered on an ambulatory basis given several factors: clear financial incentives; effective supportive care; the association of good performance status (PS) with better outcomes; and patient preference (3). Only a few malignancies require inpatient systemic treatment. Strong social support is required for safe and effective ambulatory care, thus especially challenging pts at safety net hospitals in which social constraints are common. Methods: We reviewed patterns of IPC to determine efficacy and outcomes over a 3-year period at a safety net hospital, examining: malignancy type, reason for IPC treatment, treatment regimen (typically outpatient or inpatient), length of stay, and survival. Results: 82 pts met criteria. 56% had hematologic or HIV-associated malignancies. Solid tumor types included GI, breast, GYN, GU and small cell malignancies. Reasons for IPC were progression, worsening symptoms, declining PS in 55% and social constraints in 11%. Patient death within 3 months of IPC, or direct discharge to hospice/nursing home occurred in 42%. Further outpatient chemotherapy was never given in 50%. Death occurred in 15% of pts on the same hospitalization as the IPC; several additional pts were readmitted and died within one month. Individuals receiving IPC due to poor social support frequently required rapid rehospitalization, had poor outpatient follow-up, or died shortly thereafter. Three month survival was more favorable in pts with multiple myeloma or those admitted for drug-desensitization. Conclusions: Outcomes, including survival and rapid rehospitalization, were poor for pts receiving typical outpatient regimens on an inpatient basis whether due to social constraints, declining PS or worsening symptoms. A large percentage of pts never received further chemotherapy. IPC is costly, undesired by pts, and is often not a good use of resources. Pts with highly responsive cancers with fair to good PS had acceptable outcomes. IPC should be reserved for such pts if alternative outpatient regimens are not available. Earlier discussion of hospice and goals should not be replaced by chemotherapy. Institutional unavailability of key oral agents and limited outpatient resources often contribute to IPC. Better access to modern agents, enhanced social support, enlarged and better supported outpatient resources, as well as improved decision making improve cancer care. Our results do not support IPC as a frequent approach to cancer care in safety net hospitals. 1. Popescu, JAMA 2019. 2. Farkas, JCO 2012. 3. Mor, J Clin Epid 1988.

Evaluation of a Pharmacist-Developed, Nurse-Driven Protocol for Management of Parenteral Anticancer Therapy Infusion Reactions in an Ambulatory Infusion Center

Management of infusion-related reactions in cancer therapy: strategies and challenges

The Rate of Infusion Represents an Important Aspect of Administering Anticancer Agents

Effectiveness of Pharmacist Dosing Adjustment for Critically Ill Patients Receiving Continuous Renal Replacement Therapy: a Comparative Study.

Immune-related adverse effects: Recognition and initiation of appropriate treatment in cancer patients on immunotherapy

Using QI to develop a sustainable method for titrating taxane infusions to reduce hypersensitivity reactions

Clinical characteristics and risk factors analysis of 505 cases of infusion reactions in a tertiary hospital

Rechallenges without desensitization following platinum-based chemotherapy reactions

Optimizing infusion experience for patients in GI oncology at Hartford Hospital Cancer Institute.

Infusion-related reactions with immune checkpoint inhibitors in genitourinary cancers: A systematic review and meta-analysis.

Improving medication safety in oncology care: impact of clinical pharmacy interventions on optimizing patient safety

Immune-mediated adverse event management at a tertiary care cancer center.

Infusion-Related Reaction Management With Amivantamab for EGFR Exon 20 Insertion Mutation NSCLC: A Practical Guide for Advanced Practitioners

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors

Immune-related adverse events and immunotherapy efficacy in patients with cancer: A retrospective study.

Outcomes with initiation of inpatient immunotherapy.

Disparities in cancer care: Is there a benefit for increased use of inpatient chemotherapy (IPC) in safety-net hospitals?

Improving the care of patients with lung cancer hospitalized with immune checkpoint inhibitor-related pneumonitis: Implementation of a clinical pathway algorithm.

Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center

Incidence of Immune-Related Adverse Events and Its Association with Treatment Outcomes: the MD Anderson Cancer Center Experience